Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma

Prathap Pillai, Yih-Chih Chan, Shih-Ying Wu, Line Ohm-Laursen, Clare Thomas, Stephen R Durham, Andrew Menzies-Gow, Raj K Rajakulasingam, Sun Ying, Hannah J Gould, Chris J Corrigan

Research output: Contribution to journalArticlepeer-review

53 Citations (Scopus)
182 Downloads (Pure)


Omalizumab therapy of non-atopic asthmatics reduces bronchial mucosal IgE and inflammation and preserves/improves lung function when disease is destabilised by staged withdrawal of therapy.18 symptomatic, non-atopic asthmatics were randomised (1:1) to receive omalizumab or identical placebo treatment in addition to existing therapy for 20 weeks. Bronchial biopsies were collected before and after 12-14 weeks of treatment, then the patients destabilised by substantial, supervised reduction of their regular therapy. Primary outcome measures were changes in bronchial mucosal IgE(+) cells at 12-14 weeks, prior to regular therapy reduction, and changes in lung function (forced expiratory volume in 1 s) after destabilisation at 20 weeks. Quality of life was also monitored.Omalizumab but not placebo therapy significantly reduced median total bronchial mucosal IgE(+) cells (p<0.01) but did not significantly alter median total mast cells, plasma cells, B lymphocytes, eosinophils and plasmablasts, although the latter were difficult to enumerate, being distributed as disperse clusters. By 20 weeks, lung function declined in the placebo-treated patients but improved in the omalizumab treated patients, with significant differences in absolute (p=0.04) and % predicted forced expiratory volume in 1 s (p=0.015).Omalizumab therapy of non-atopic asthmatics reduces bronchial mucosal IgE(+) mast cells and improves lung function despite withdrawal of conventional therapy.

Original languageEnglish
JournalEuropean Respiratory Journal
Early online date20 Oct 2016
Publication statusE-pub ahead of print - 20 Oct 2016


Dive into the research topics of 'Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma'. Together they form a unique fingerprint.

Cite this